Cargando…

Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature

BACKGROUND & AIMS: Several observational studies have recently reported the outcomes of non-insulin anti-diabetic agents (ADA) in patients with T2DM and coronavirus disease 2019 (COVID-19). We sought to review the literature to appraise the clinicians on these outcomes. METHODS: A literature sea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Awadhesh Kumar, Singh, Ritu, Saboo, Banshi, Misra, Anoop
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Diabetes India. Published by Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832723/ https://www.ncbi.nlm.nih.gov/pubmed/33352455 http://dx.doi.org/10.1016/j.dsx.2020.12.026

Ejemplares similares

Triglyceride and cardiovascular risk: A critical appraisal
por: Singh, Awadhesh Kumar, et al.
Publicado: (2016)

Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Molnupiravir in COVID-19: A systematic review of literature
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19()
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Gujarat cohort of the A(1)chieve study
por: Saboo, Banshi, et al.
Publicado: (2013)

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Key elements of successful intensive therapy in patients with type 1 diabetes
por: Saboo, Banshi
Publicado: (2015)

“Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Clinical considerations for patients with diabetes in times of COVID-19 epidemic
por: Gupta, Ritesh, et al.
Publicado: (2020)

Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Metformin in gestational diabetes: An emerging contender
por: Singh, Awadhesh Kumar, et al.
Publicado: (2015)

Diabetes Monotherapies versus Metformin-Based Combination Therapy for the Treatment of Type 2 Diabetes
por: Singh, Awadhesh K, et al.
Publicado: (2021)

Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence
por: Sosale, Aravind, et al.
Publicado: (2015)

Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence
por: Singh, Awadhesh Kumar, et al.
Publicado: (2016)

Letter by Awadhesh Kumar Singh Regarding Article, “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis”
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Does poor glucose control increase the severity and mortality in patients with diabetes and COVID-19?
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Noninsulin‐based antihyperglycemic medications in patients with diabetes and COVID‐19: A systematic review and meta‐analysis
por: Nassar, Mahmoud, et al.
Publicado: (2023)

Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

RSSDI’s Defeat Diabetes Campaign: India takes a major leap in the direction of diabetes care capital of the world
por: Saboo, Banshi, et al.
Publicado: (2021)

Suggested use of vaccines in diabetes
por: Kesavadev, Jothydev, et al.
Publicado: (2012)

Bariatric surgery and diabetes remission: Who would have thought it?
por: Singh, Awadhesh Kumar, et al.
Publicado: (2015)

Current Practices and Gaps in Management of Dyslipidemia in Type 2 Diabetes Mellitus (T2DM) in Accordance with American Diabetes Association (ADA) Guidelines: A Subset Analysis from a Real-World, Cross-Sectional Observational Study (LEADD Study)
por: Das, Ashok Kumar, et al.
Publicado: (2021)

RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus
por: Kumar, Vasanth, et al.
Publicado: (2022)

Editorial: Herd mentality, herds of migrants/people, and COVID-19 in India
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Impact of COVID-19 and comorbidities on health and economics: Focus on developing countries and India
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Letter to the editor in response to the article: “Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis (Kumar et al.)”
por: Kumar Singh, Awadhesh, et al.
Publicado: (2020)

Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
por: Das, Ashok Kumar, et al.
Publicado: (2023)

Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians
por: Singh, Awadhesh Kumar, et al.
Publicado: (2019)

Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review
por: Singh, Awadhesh Kumar, et al.
Publicado: (2016)

Incretin response in Asian type 2 diabetes: Are Indians different?
por: Singh, Awadhesh Kumar
Publicado: (2015)

Remission of type 2 diabetes: A critical appraisal
por: Ricci, Michele, et al.
Publicado: (2023)

Continuous subcutaneous insulin infusion: practical issues
por: Saboo, Banshi D., et al.
Publicado: (2012)

Can anti-Mullerian hormone replace ultrasonographic evaluation in polycystic ovary syndrome? A review of current progress
por: Singh, Awadhesh Kumar, et al.
Publicado: (2015)

Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.)
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hrljgvctp8pq6h5vtb8sh3s2lm